Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

ConferencePharmacology and drug development · Paris, France

ESMO Targeted Anticancer Therapies Congress 2027

The ESMO Targeted Anticancer Therapies Congress 2027 takes place at the Palais des Congrès, Paris, from 22 to 24 February 2027 and is aimed at professionals in early clinical drug development and translational oncology research. This guide covers areas consistent with the congress scope, readiness checks for abstracts, and what to consider before the 1 December 2026 deadline.

Pubrica InsightsEditorial team, reviewed by a subject specialist
Next deadline
1 December 2026
Last checked
10 November 2026
Organiser
European Society for Medical Oncology
Sources
1
Submit an abstract

Key dates

Abstract deadline
1 December 2026
Full paper deadline
Abstracts only, or not stated
Conference dates
22 February 2027 – 24 February 2027
Details last checked
10 November 2026
Submit an abstract

About the conference

Conference
ESMO Targeted Anticancer Therapies Congress 2027
Organiser
European Society for Medical Oncology
Venue
Paris, France
Scope
ESMO congress for professionals in early clinical drug development and translational oncology research, held at the Palais des Congrès, Paris.
Submission types
Abstracts; confirm formats and word limits on the official page

Topics consistent with the programme

  • Phase I and first-in-human trials of novel anticancer agents
  • Biomarker-driven patient selection in early drug development
  • Mechanisms of response and resistance to targeted therapies
  • Antibody–drug conjugates and novel therapeutic modalities
  • Pharmacokinetics, pharmacodynamics and dose optimisation in oncology
  • Preclinical models supporting translation of targeted agents

Based on the published scope; the official page sets out the full themes and requirements.

Is your work a fit? Check before you submit

  1. The work addresses early clinical drug development or translational oncology research.
  2. The abstract reports original data with clear methods and results.
  3. Clinical data are reported with ethical approval and appropriate safety reporting.
  4. The abstract category and submission rules have been confirmed on the official ESMO meeting page.
  5. The abstract is complete, approved by all co-authors and submitted before 1 December 2026.

Why This Conference Matters

Early clinical development is where new anticancer agents are first tested in patients, and decisions about dosing, biomarkers and patient selection made at this stage shape later success. This congress focuses specifically on that phase and on the translational research that supports it, bringing together clinical investigators, translational scientists and drug developers. Presenting gives authors a focused audience with direct interest in novel agents and early-phase methodology.

Who Should Submit

Academic backgrounds

  • Medical oncology
  • Clinical pharmacology
  • Translational cancer research
  • Molecular pathology
  • Biostatistics and trial methodology

Institutions and sectors

  • Phase I units and cancer centres
  • Pharmaceutical and biotechnology companies
  • Academic translational research laboratories
  • Contract research organisations

What Reviewers Typically Value

  1. Early clinical data on novel agents with clear safety and activity reporting.
  2. Biomarker work that clarifies which patients benefit from targeted therapies.
  3. Mechanistic insights into resistance with implications for drug development.
  4. Innovative early-phase trial designs or dose optimisation approaches.

Ideas You Could Develop

First-in-human dose escalationA phase I study reporting safety, pharmacokinetics and preliminary activity of a novel targeted agent.
Resistance mechanisms from paired biopsiesA translational study using paired biopsies to identify mechanisms of acquired resistance to a targeted therapy.
Model-informed dose optimisationA pharmacometric analysis supporting selection of an optimal dose for an oncology agent in expansion cohorts.

Your Plan to the Deadline

A suggested schedule working back from 1 December 2026. Adjust it to the stage your work has reached.

  1. By 20 Oct 2026

    Open the official call for abstracts; confirm the tracks, word limit, format and author rules.

  2. By 3 Nov 2026

    Agree the key result, the authors and the presenting author.

  3. By 17 Nov 2026

    Draft the structured abstract to the word limit, with results stated as numbers.

  4. By 24 Nov 2026

    Circulate to co-authors and an independent reader; revise.

  5. By 29 Nov 2026

    Final checks: title, author affiliations, conflicts of interest and track selection.

  6. By 1 Dec 2026

    Submit through the official abstract system before the deadline.

What you gain

  • Feedback from peers working on the same questions.
  • A citable abstract or proceedings paper.
  • Contacts for collaboration, employment and future funding.
  • A step towards a full journal article.

What happens after you submit

  1. Acknowledgement: the abstract system confirms receipt; keep the submission number.
  2. Review: the scientific committee scores abstracts against the track criteria.
  3. Decision: accepted abstracts are assigned to an oral, poster or e-poster session.
  4. Registration: presenting authors usually must register by a stated date.
  5. Publication: accepted abstracts or papers may appear in the conference proceedings or journal supplement.

What the Organisers Are Looking For

ESMO invites abstracts on early clinical drug development and translational oncology research. Organisers are likely to look for original data on novel agents, biomarkers and mechanisms with relevance to developing better cancer therapies. Authors should confirm abstract categories, formatting and rules on the official ESMO meeting page before the 1 December 2026 deadline.

Read the official pageThis guide summarises the opportunity. Confirm deadlines, eligibility and requirements on the official page before you plan your work, and record the date you checked it.Open the official page

Expert help

How Pubrica Can Help

Pubrica’s subject specialists can help you prepare the abstract, full paper, poster or slides, planned back from the deadline. You remain the author of your work.

Abstract writingA structured abstract written to the conference’s word limit and format. Full paper writingFull conference papers written to the proceedings template. Poster preparationScientific posters designed to the conference’s size and layout rules. Presentation slidesOral presentation slides prepared for the allotted time. Editing and proofreadingSubject-specialist editing of abstracts and papers before submission. BiostatisticsStatistical analysis and review of results.
Go to the official page

FAQs

Questions Researchers Ask

The next published deadline is 1 December 2026. Dates can change, so confirm them on the official page before you plan your work.

The congress focuses on early clinical drug development and translational oncology, so preclinical work with clear translational relevance may fit. Authors should check the abstract categories on the official ESMO meeting page to confirm.

The official page lists abstract submission; check it for any full paper or proceedings option.

Yes. Pubrica’s specialists can review, write, edit and format your abstract, paper, poster or slides. You remain the author and the person responsible for the submission.

Sources

  1. European Society for Medical Oncology. (2026). ESMO Targeted Anticancer Therapies Congress 2027. Retrieved 10 November 2026, from https://www.esmo.org/meeting-calendar/esmo-targeted-anticancer-therapies-congress-2027

How to cite this page

Pubrica Insights. (2026). ESMO Targeted Anticancer Therapies Congress 2027. Pubrica. https://pubrica.com/insights/calls-and-conferences/esmo-targeted-anticancer-therapies-congress-2027/

  • Targeted therapy
  • Early drug development
  • Translational oncology
  • ESMO TAT 2027
  • Paris

Other Open Conferences

Closes 16 November 202636th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2027)Australia Closes 18 November 2026ESCMID Global 2027Sweden Closes 19 November 2026ESC Preventive Cardiology 2027Portugal

All calls, conferences and fundingAbstract writing

ESMO TAT 2027Next deadline 1 December 2026

Official page
Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.